The question

For the two RetaSet listings checked on September 27, 2026, the difference is straightforward: GLOW lists GHK-Cu, BPC-157 and TB-500; KLOW lists those three plus KPV. What does not follow is that the fourth ingredient makes KLOW more effective, safer or appropriate for a particular person. Those are separate research questions.

The useful comparison starts with the exact listings, then asks whether the evidence actually studied that combination. A memorable blend name is a convenient catalog label. It is not enough information to identify a clinical intervention.

A closer look at these two labels

RetaSet’s GLOW product image lists GHK-Cu 50mg, BPC-157 10mg and TB-500 10mg, totaling 70mg. Its KLOW description lists those same amounts plus KPV 10mg, totaling 80mg. These are supplier-declared contents, not independent measurements made for this article. GLOW listing; KLOW listing.

There is a small but useful documentation detail: the KLOW image names BPC-157 without printing its amount on the ingredient line, while the written description supplies 10mg. That is a reason to read the complete listing and batch documentation rather than treating one image as a complete specification. We did not authenticate a batch-specific COA or physically examine either product.

Nor should the totals become an effectiveness comparison. The extra 10mg describes the stated composition. It does not measure an extra amount of healing, and it is not a treatment instruction. A study would need to specify the material, formulation and route, not just a total mass and a blend nickname.

What adding KPV changes in the evidence question

KPV has a research literature, but an ingredient paper and a blend trial answer different questions. In a 2008 study, Dalmasso and colleagues examined KPV in intestinal and immune cell models and in two experimentally induced mouse colitis models. They reported effects on inflammatory signaling and measures of intestinal inflammation. This was preclinical work, not a trial of KLOW in patients. Original study abstract.

The distinction is particularly easy to miss when a paper uses human-derived cells. “Human cells” describes the laboratory model; it does not mean people received the intervention and experienced a clinical benefit. In this example, the study also did not compare a three-ingredient blend against a four-ingredient blend. Its findings cannot establish that adding KPV improves either commercial product.

FDA’s KPV briefing document prepared for the July 2026 compounding advisory meeting reported that its evaluation had not identified clinical studies of KPV administered to humans. Read that as a dated regulatory evidence assessment, with its own search scope—not a promise that research will never develop. FDA KPV briefing, pages 19–20 and 25–26.

One ingredient name can hide another mismatch

TB-500 adds a separate identity problem. FDA’s July 2026 briefing describes the evaluated TB-500 as an acetylated seven-amino-acid fragment, while full-length thymosin beta-4 has 43 amino acids. It also explains why findings for a non-acetylated fragment cannot simply be assigned to the acetylated substance. FDA TB-500 briefing, pages 24–26.

For a reader checking a reference list, that creates a concrete task: compare the paper’s actual substance with the product’s stated identity. Do not stop when the names look related. The same discipline applies to formulation and route. A result from a topical preparation does not automatically establish what a multi-ingredient injectable mixture would do. FDA separately identifies limited human safety information and potential aggregation or impurity concerns for injectable GHK-Cu. FDA safety-risk information.

What would a persuasive comparison need?

Imagine a study reporting improvement after a four-ingredient blend. Without a suitable comparator, it cannot isolate the contribution of ingredient four. To answer whether adding KPV changes outcomes, a comparison would need to account for the other ingredients, formulation, population, follow-up and measured outcome. This is an editorial explanation of study design, not a proposed self-experiment.

Our September 27 ClinicalTrials.gov API searches for intervention “KLOW” and for “GLOW” combined with “peptide” returned no records. That narrow name search is not proof that every possible synonym or ingredient combination has been exhaustively searched. We identified no direct comparative human trial supporting a GLOW-versus-KLOW effectiveness ranking in the sources reviewed. ClinicalTrials.gov.

There is also a regulatory distinction. FDA’s July meeting considered individual bulk substances for compounding and explicitly describes advisory recommendations as non-binding. A committee discussion does not grant approval to either catalog blend. Compounded drugs themselves are not FDA-approved. Neither product page provides an FDA-approved drug label for the blend. FDA meeting record; FDA compounding explanation.

BPC-157 human evidence · GHK-Cu skin research · How to read a peptide COA

Sources & further reading

  1. Original study abstract
  2. FDA KPV briefing, pages 19–20 and 25–26
  3. FDA TB-500 briefing, pages 24–26
  4. FDA safety-risk information
  5. ClinicalTrials.gov
  6. FDA meeting record
  7. FDA compounding explanation

Research context last reviewed September 27, 2026. Last updated September 27, 2026. Educational reading, not individual medical advice. How this article was prepared.